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Dendritic cells were discovered by Ralph Steinman and Zan-
vil Cohn a little more than three decades ago (Steinman and
Cohn, 1973). I became interested in the topic about 20 y ago
while I was a postdoctoral fellow. At that time, it was possible
to read every paper that focused on dendritic cells, to ‘‘un-
derstand’’ the information that was presented, and to fit that
information into a relatively simple conceptual framework.
The subsequent recognition that dendritic cells are of critical
importance in immunophysiology resulted in dramatically
heightened interest in this fascinating cell type, and this in
turn has resulted in an explosion of information that is in-
creasingly difficult to become aware of and to synthesize,
even for serious students of dendritic cells. This difficulty re-
flects not only the volume of the information that is published,
but also its complexity. Since dendritic cells both initiate and
shape T cell-dependent immune responses, studies of den-
dritic cell function are also studies of T cell biology and T cell
function, with all the complexity that this entails. The article in
the current issue by Mizumoto et al (2005) informs us that
dendritic cell complexities extend to intracellular signaling
pathways that are differentially engaged as dendritic cells
respond to various stimuli. This complexity must also be
carefully explored if we are to fully understand dendritic cells,
and how to manipulate them for patient benefit. Because
dendritic cell biology is a complicated topic, it may be helpful
to put the studies of Mizumoto et al (2005) into context.
Dendritic cells are bone marrow-derived cells that can be
found in all lymphoid, and almost all non-lymphoid, tissues.
Dendritic cells in different tissues may differ from each other
with regard to function as well as phenotype. A major func-
tion of dendritic cells is to initiate antigen-specific immune
responses in naı¨ve T lymphocytes and to influence the char-
acter of the immune responses that subsequently develop.
Dendritic cells are also responsive to microenvironmental
influences, and their functional properties are dependent on
what is going on around them. Thus, the ideal way to explore
dendritic cell function is to study dendritic cells in situ while
they are participating in immune or inflammatory responses.
Obviously, immune responses that are evolving in vivo are
inherently complicated. Typically, in vivo experiments require
painstaking development and characterization of animal
models that often allow only highly focused questions to be
addressed. In addition, definitive answers may be difficult to
obtain. In vivo experiments involving human dendritic cells
are problematic for other reasons. Thus, model systems that
allow dendritic cell biology to be studied in vitro have been,
and are, essential to make progress.
The field made a leap forward when a number of inves-
tigators developed methodology that allowed routine prop-
agation of dendritic cells from human and murine blood-
and bone marrow-derived precursors in primary cultures
(Caux et al, 1992; Inaba et al, 1992a, b; Sallusto and La-
nzavecchia, 1994). The availability of these cells for study in
many laboratories around the world enabled rapid progress
that underpins much of what we know about dendritic cells
today. For example, homogeneous populations of dendritic
cells derived from in vitro cultures allowed identification of
physiologic dendritic cell agonists (including microbial prod-
ucts and cytokines), definition of cell surface receptors
through which these agonists act, and detailed character-
ization of the ways dendritic cells influence T cell function.
Studies of dendritic cells that have been grown in primary
cultures in laboratories have limitations, however. One lim-
itation is that dendritic cells that are grown in different lab-
oratories, or even in the same laboratory at different times,
may have different characteristics. This frustrating occur-
rence probably reflects the sensitivity of dendritic cells to
even minor changes in microenvironmental or culture con-
ditions. In addition, the phenotypes of laboratory dendritic
cells are not identical to even the tissue dendritic cells that
they most closely resemble. Finally, dendritic cells grown in
primary cultures are not amenable to certain kinds of ex-
perimental manipulations. Most notable are experiments
that require introduction of genes of interest, such genes
encoding active or inhibitory variants of signaling mole-
cules, into dendritic cells by transfection or transduction.
Dendritic cell lines, including the XS106 cell line used in
the paper by Mizumoto et al (2005), have their own utilities
and limitations. Virtually unlimited capacity for growth and
consistency over time are major benefits of cell lines. De-
spite the fact that the XS106 line was initially described
more than 5 y ago (Timares et al, 1998), its major charac-
teristics have not changed. Some dendritic cell lines, in-
cluding the XS106 cell line, remain responsive to known
dendritic cell agonists, making them suitable for cell acti-
vation studies such as those described in the Mizumoto
paper. Most dendritic cell lines retain some dendritic cell
surface markers as well as the ability to initiate antigen-
dependent activation of T cells, and this is certainly true of
XS106 cells. With regard to limitations, the degree to which
dendritic cell lines can be activated is typically attenuated
as compared with that of dendritic cells in tissues or dendri-
tic cells in primary cultures. In addition, the extent to which
dendritic cell lines resemble tissue dendritic cells is even
more limited than it is for dendritic cells that are generated
in primary cultures. Finally, it is generally accepted that den-
dritic cells in tissues are ‘‘end stage’’ cells that have lost their
proliferative potential. Although the XS106 cell line retains
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growth factor (GM-CSF and M-CSF)-dependence, its prolif-
erative capacity far exceeds that of tissue dendritic cells. This
latter characteristic of XS106 cells may be particularly rele-
vant for, and potentially a confounder of, studies of tran-
scription factor activity such as those described in this issue.
Mizumoto and coworkers are well aware of both the
positive and negative attributes of the cells used in their
studies. Over the past ten years, Akira Takashima’s group
has repeatedly and creatively used dendritic cell lines that
they have developed and characterized dendritic cell lines
to initiate studies of fundamental aspects of dendritic cell
biology that they have subsequently confirmed in normal
cells or in tissues (Xu et al, 1995). These investigators have
also used dendritic cell lines to perform proof-of-concept
experiments of novel dendritic cell-based therapies that
have efficacy in animal models (Timares et al, 2003; Matsue
et al, 1999). This issue of the JID reports yet another inno-
vative and careful study from this group that could only have
been carried out with a dendritic cell line.
Although microbial products, cytokines and growth fac-
tors, exogenous chemicals, and endogenous cellular met-
abolites that activate dendritic cells have been catalogued
and much is known about receptors that are engaged by
these dendritic cell agonists, information about how intra-
cellular responses to these agents are integrated is limited.
Typically, elucidation of the importance of signal transduct-
ion pathways in biological responses has involved making
specific predictions, choosing appropriate pharmacologic
activators or inhibitors (or mutated genes that encode active
or inhibitory members of the pathway(s) of interest), intro-
ducing them into cells, and determining whether or not the
intervention chosen has the predicted effect.
The study by Mizumoto et al (2005) is distinctly different in
that the experimental approach does not require prediction
of outcomes. Rather, the authors have systematically cat-
aloged the involvement of 15 different transcription factors in
response to 14 different known dendritic cell agonists in a
totally unbiased way. Not so long ago, a study like this might
have been criticized for being a ‘‘fishing expedition’’ that was
not ‘‘hypothesis driven’’. Interestingly, in 2005, we have come
to regard this kind of investigation as ‘‘hypothesis generat-
ing’’ and, based on the power of the approach and the fre-
quency with which it is successful, to value it. The agonists
chosen for study include microbial products, endogenous
metabolites, and exogenous agents that are known to ac-
tivate dendritic cells in vivo as well as in vitro. Transcription
factor activity was assessed by introducing reporter gene
expression constructs that are comprised of cDNAs that en-
code firefly luciferase, a protein that can be readily quantified
via a sensitive chemiluminescence assay, located down-
stream of well characterized enhancer elements into the
XS106 dendritic cell line using standard transfection meth-
odology. Previous studies involving other cells had deter-
mined that increased production of luciferase in cells tran-
sfected with the individual constructs was a good surrogate
marker of activation of the selected transcription factor.
The paper by the Takashima group is clearly written, so
there is no need to detail the results. To summarize briefly,
the paper describes overlapping and non-random utilization
of arrays of transcription factors in response to the various
agonists tested. Using hierarchical clustering analysis, ago-
nists using the same or similar transcription factors could be
grouped. The largest cluster is broad, meaning that there is
incomplete overlap in the transcription factors that are uti-
lized, and includes responses to most dendritic cell stimula-
tors. More studies will be required to determine whether or
not this cluster can be additionally subdivided. In addition to
and in light of the limitations of in vitro studies and studies of
dendritic cell lines that were discussed above, it will be im-
portant to carry out selected in vivo experiments to support
or refute major conclusions of this study. Regardless of the
outcome of these in vivo studies, however, the experimental
system described by Mizumoto et al (2005) will be very
useful. For example, it may constitute a platform that will
facilitate directed or non-directed high throughput testing of
agents that could become dendritic cell modulating drugs
that will ultimately be useful in patients with cancer, chronic
infections, or autoimmune diseases. In addition, the exper-
imental system may prove to be useful as a component of a
screen that could be used to assess the possible irritancy or
potential antigenicity of environmental contactants, topical
medications, or cosmetics.
For those who are actively engaged in laboratory inves-
tigations, the paper also serves as a reminder that there is
great value in devoting time to actively think about innovative
ways to utilize existing reagents and methodologies to ask
important new questions. I know that Dr Takashima’s group
includes a number of avid fishermen, including Dr Takashima
himself. I cannot help but wonder if their appreciation for
some of the finer things in life, like cold beer and time spent
in a boat on a lake or in the Gulf with live bait or a lure in the
water, has something to do with their sustained creativity.
Perhaps it is these interludes that enable them to do their
best work, and the sign on the door that says ‘‘Gone Fishin’’’
is a prelude to the next series of interesting investigations.
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